# A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

> **NCT06973005** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 16 (actual)

## Conditions studied

- Advanced Chronic Liver Disease
- Healthy Participants

## Interventions

- **DRUG:** AZD2389
- **DRUG:** Midazolam
- **DRUG:** Caffeine
- **DRUG:** Bupropion

## Key facts

- **NCT ID:** NCT06973005
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-08
- **Primary completion:** 2025-07-18
- **Final completion:** 2025-07-18
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973005, "A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06973005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*